SEASON 3 EPISODES - SPONSORED BY BRISTOL MYERS SQUIBB 

HCMS Podcast Episode 32
Bionic Tech and Shared Decisions: Exploring the Spectrum of ICD Care in HCM
Dr. John Fritzlen joins leading electrophysiologist Dr. Mark Link and Hannah and Bethany from Heart Charged to discuss the critical role of implantable cardioverter-defibrillators (ICDs) in managing hypertrophic cardiomyopathy. The group navigates the complex clinical landscape of ICD indications, including the importance of MRI findings and specific risk factors like non-sustained ventricular tachycardia (NSVT). Dr. Link provides an expert comparison of transvenous, subcutaneous (S-ICD), and the latest extravascular (EV-ICD) technologies, focusing on device durability and suitability for active patients. Throughout the conversation, the "Bionic Babes" of Heart Charged offer invaluable patient perspectives on life with a defibrillator, the necessity of shared decision-making, and the evolving guidelines that now encourage vigorous exercise for those living with the condition.

HCMS Podcast Episode 31
Redefining the Standard: Insights from the MAPLE Trial in Obstructive HCM
Dr. Florian Rader and Dr. Ahmad Masri discuss the results of the MAPLE trial, a head-to-head study comparing aficamten—a cardiac myosin inhibitor—to metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy. The trial utilized a "double-blind" design while testing both medications at therapeutic doses to assess patient’s quality of life, cardiorespiratory fitness and cardiac biomarkers. Dr. Masri highlights unexpected findings, including the significant reduction in peak VO2 and the worsening of cardiac biomarkers like NT-proBNP in the metoprolol group. The conversation also explores how these results challenge decades of reliance on beta-blockers as a first-line therapy and demonstrate the efficacy of aficamten as a potential upfront monotherapy for improving patient feel and function. 

HCMS Podcast Episode 30
Decoding Refractory Symptoms: Advanced Diagnosis and Management in HCM
Dr. Madeline Smoot talks with Dr. Alex McNamara to discuss the complexities of managing refractory symptoms in patients with hypertrophic cardiomyopathy (HCM). The conversation highlights the distinction between obstructive and non-obstructive symptoms, emphasizing the importance of provocative testing—such as cardiopulmonary exercise testing (CPET) and gold-directed Valsalva maneuvers—to unmask "labile" obstruction that resting echoes might miss. They explore the evolving role of cardiac myosin inhibitors and the potential impact of GLP-1 agonists on obesity-related symptom burden. Additionally, Dr. McNamara provides insights into identifying red flags.

HCMS Podcast Episode 29
The "Neglected Middle": Redefining HCM Genetics with Intermediate Effect Variants
Genetic counselor Matthew Thomas sits down with Dr. Roddy Walsh and Dr. Juan Pablo Ochoa to discuss their groundbreaking research on the genetic architecture of Hypertrophic Cardiomyopathy (HCM). The conversation centers on "Intermediate Effect Variants" (IEVs)—genetic markers that fall between rare, high-impact Mendelian mutations and common, low-impact polygenic risk factors. By utilizing a massive dataset of over 20,000 patients and robust ancestry-matched controls, the researchers demonstrate how these variants contribute to disease severity, age of onset, and wall thickness. This episode explores the practical implications for clinical genetic testing, the necessity of diverse genomic data, and how these findings are shifting the field toward a more quantitative and comprehensive understanding of HCM risk.  (References: https://www.ahajournals.org)

HCMS Podcast Episode 28
The Center of Excellence: Redefining Specialized Care in HCM
Dr. Betty Raman interviews Dr. Srihari Naidu, Director of the Hypertrophic Cardiomyopathy Medical Center at Westchester Medical Center, to explore what truly defines a "Center of Excellence". Dr. Naidu shares how his philosophy has evolved from a structural focus on advanced imaging and surgical tools to a patient-centered approach that prioritizes individualized care and a multidisciplinary "heart team". The discussion highlights the critical role of specialized centers in navigating complex differential diagnoses—such as amyloidosis or mitochondrial HCM—and the importance of shared decision-making in sudden cardiac death risk stratification. Dr. Naidu also provides a practical roadmap for clinicians looking to establish regional HCM services, emphasizing the necessity of robust echo protocols and strong collaborative networks for advanced procedures.

HCMS Podcast Episode 27
Metabolic Modulation in Non-Obstructive HCM: Exploring the FORTITUDE Trial
Dr. Betty Raman and Dr. James MacNamara welcome Professor Martin Maron, Director of the Hypertrophic Cardiomyopathy Center at Lahey Hospital & Medical Center, to discuss the innovative FORTITUDE-HCM study. This Phase 2b trial focuses on the symptomatic non-obstructive HCM population—a group considered to have one of the greatest unmet treatment needs in the field. The conversation explores the unique mechanism of ninerafaxstat, a metabolic modulator that shifts energy utilization from fatty acids to glucose to improve cardiac energetics and diastolic relaxation. Professor Maron highlights the promising results from the earlier IMPROVE-HCM trial, details the 12-week design of the current study, and speculates on a future where "combination therapy" becomes the standard of care for complex HCM cases.

HCMS Podcast Episode 26
The SONATA Trial: SGLT2 Inhibition as a New Frontier in HCM Treatment
Dr. James MacNamara sits down with Dr. Sharlene Day, Director of Translational Research at the University of Pennsylvania, to discuss the groundbreaking SONATA trial. This double-blind, placebo-controlled clinical trial is evaluating the safety and efficacy of sotagliflozin—a dual SGLT1 and SGLT2 inhibitor—in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy. Dr. Day details the trial's unique design, its primary endpoint of improving the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, and the fascinating metabolic mechanisms that may allow these drugs to reduce the heart's workload. The conversation also covers the safety protocols for monitoring outflow tract obstruction and the potential pleiotropic benefits of SGLT2 inhibitors beyond traditional heart failure management.

HCMS Podcast Episode 25
Teamwork, Tech, and Tomorrow: Highlights from the 2025 Scientific Sessions
Dr. James MacNamara and Dr. Betty Raman recap the latest annual Hypertrophic Cardiomyopathy Society (HCMS) scientific sessions held in New Orleans. The discussion emphasizes that HCM care is a "team sport," involving a multidisciplinary coalition of physicians, pharmacists, and advanced practice providers. Key highlights include a deep dive into Professor Hugh Watkins' lecture on the future of gene therapy and the impact of polygenic risk scores on disease penetrance. They also explore the evolving landscape of HCM treatment—comparing the roles of cardiac myosin inhibitors versus surgical interventions—and share promising new data on the safety and efficacy of moderate-intensity exercise for non-obstructive patients.

HCMS Podcast Episode 24
Seeing HCM Clearly: Optimizing Echocardiography for Better Diagnosis
How can echocardiographers improve the accuracy and confidence of hypertrophic cardiomyopathy diagnosis? In this episode of In the Thick of It, sonographers Amy Dillenbeck and Brad Mehl explore the essential role of echocardiography in evaluating HCM, sharing best practices for optimizing imaging techniques, Doppler assessment, and contrast use. They discuss the most common challenges in detecting HCM, how to train sonographers to recognize subtle diagnostic clues, and strategies to avoid misinterpretation. Whether you're a seasoned clinician or new to HCM imaging, this episode offers valuable insights into refining echocardiographic evaluation for better patient outcomes.

HCMS Podcast Episode 23
Understanding NSVT: Risk Assessment and ICD Decisions in HCM
How do we determine which hypertrophic cardiomyopathy patients are at the highest risk for sudden cardiac death? In this episode of In the Thick of It, Dr. Steve Ommen and Dr. Mark Link take a deep dive into the role of non-sustained ventricular tachycardia (NSVT) in risk assessment and ICD decision-making. They discuss how age, VT duration, and other clinical factors influence risk stratification, as well as the evolving guidelines on ICD placement. The conversation also covers the latest advancements in device technology and the nuances of selecting the right ICD for each patient. Don’t miss this essential discussion on refining risk assessment and improving outcomes in HCM care. 

HCMS Podcast Episode 22
Imaging Matters: How LGE Guides HCM Management
How can late gadolinium enhancement (LGE) on cardiac MRI help predict sudden cardiac death risk in hypertrophic cardiomyopathy? In this episode of In the Thick of It, Dr. Christopher Kramer and Dr. Raymond Chan explore the clinical significance of LGE, from its role in ICD decision-making to the challenges of scar quantification. They discuss how to differentiate true myocardial scar from artifacts, the evolving guidelines on LGE thresholds, and the implications of advanced imaging techniques for HCM management. Tune in for expert insights on integrating LGE into risk assessment and optimizing patient care. 

HCMS Podcast Episode 21
Valve Disease and HCM: Predicting and Preventing Complications
How do hypertrophic cardiomyopathy and aortic valve disease intersect, and what makes managing these patients so challenging? In this episode of In the Thick of It, Dr. Srihari Naidu and Dr. Megan Coylewright explore the complexities of aortic valve replacement (TAVR) in patients with HCM. What challenges arise when HCM patients undergo aortic valve replacement, and how can these risks be mitigated? They discuss the risks of left ventricular outflow tract obstruction, strategies to optimize patient outcomes, and the importance of distinguishing HCM from other conditions like amyloidosis. Tune in to learn about the role of advanced imaging, careful patient selection, and multidisciplinary heart teams in managing these overlapping conditions effectively.

HCMS Podcast Episode 20
Cracking the Code: The Role of Genetics in HCM Diagnosis, Screening and Treatment
How has genetic testing transformed the understanding and care of hypertrophic cardiomyopathy? In this episode of In the Thick of It, Dr. Victoria Parikh and genetic counselor Tia Moscarello from the Stanford Center for Inherited Cardiovascular Disease explore the powerful role of genetics in HCM diagnosis, family screening, and treatment. They discuss groundbreaking advancements like gene therapy, precision medicine, and the evolving understanding of variants of uncertain significance (VUS). Tune in to learn how genetic insights are driving early detection, personalized therapies, and even potential cures for HCM, offering hope for patients and their families.

HCMS Podcast Episode 19
From Imaging to Intervention: Navigating Apical Aneurysms in HCM
What are left ventricular apical aneurysms, and why do they pose such a high risk in hypertrophic cardiomyopathy patients? In this episode of In the Thick of It, Dr. Ethan Rowin and Dr. Jeffrey Geske delve into this rare but critical HCM phenotype. They discuss how to accurately define and detect apical aneurysms, the importance of advanced imaging techniques like contrast echocardiography and cardiac MRI, and the elevated risks of sudden cardiac death and stroke these patients face. This insightful conversation also provides insights into the evolving guidelines for ICD placement and the nuanced role of aneurysm size in risk stratification. Don’t miss this deep dive into one of HCM’s most challenging presentations.

HCMS Podcast Episode 18
Managing HCM in Pediatric Patients: Why Early Detection Matters
Why is early detection of hypertrophic cardiomyopathy in children so critical for effective treatment? In this episode of In the Thick of It, Dr. Matthew Martinez sits down with pediatric cardiologist Dr. Tess Saarel to explore the unique challenges of managing HCM in young patients. They discuss the importance of personalized risk assessments, the role of genetics in tailoring care, and the collaborative efforts needed to improve outcomes in pediatric HCM. Join them for an insightful conversation on the evolving landscape of pediatric cardiology in HCM care.

HCMS Podcast Episode 17
Complex Layers: Screening for and Monitoring Comorbidities in HCM
What makes managing common conditions like hypertension and sleep apnea uniquely challenging in hypertrophic cardiomyopathy patients? In this episode of In the Thick of It, Dr. Michael Ayers and Dr. Robyn Bryde tackle the complexities of treating comorbidities such as obesity and type 2 diabetes within the context of HCM. They delve into how obstructive physiology impacts treatment choices and share key considerations for surgical clearance, all aimed at optimizing patient outcomes. Tune in for practical insights into managing the multifaceted health needs of HCM patients.

HCMS Podcast Episode 16.
Understanding the Impact of Atrial Fibrillation in HCM  Patients
What does it take for healthcare providers to meet the unique needs of HCM patients experiencing AFib? In this episode, Dr. Ethan Rowin and Dr. Jose Joglar delve into the critical topic of atrial fibrillation (AFib) in patients with hypertrophic cardiomyopathy (HCM). They discuss the heightened risk of stroke associated with AFib, the necessity for prompt anticoagulation, and the complexities of maintaining rhythm control. Tune in to gain pivotal insights into effective treatment strategies, including anti-arrhythmic medications and left atrial appendage closure devices, and discover the importance of comprehensive care and lifestyle management to improve outcomes for HCM patients facing AFib. 

HCMS Podcast Episode 15.
Educating Patients & Families About Genetic Implications of HCM
In today’s episode of In the Thick Of It, Dr.  Anna Woo is joined by Dr. Sharon Cresci for a conversation on hypertrophic cardiomyopathy and its genetic implications. What role does genetic testing play in identifying familial variants and whether inheriting a pathogenic variant will lead to disease? Learn about the importance of genetic testing, lifelong serial screening, collaborative treatment approaches, and the processes of educating patients and families about HCM. Tune in as these experts provide insights on vigilance, follow-up care, and informed decision-making in HCM management.

HCMS Podcast Episode 14.
Surgical Considerations with Septal Myectomy and Mitral Valve Repair in HCM
Dr. Benjamin Van Boxtel welcomes Dr. Daniel Swistel and Dr. Joseph Dearani to discuss Septal Myectomy and mitral valve repair. Why is personalized patient care crucial when managing hypertrophic cardiomyopathy? Tune in as these specialists explore the importance of customized procedures, teamwork across disciplines, ongoing education, and staying abreast of the latest technological advancements in the field. Dr. Swistel and Dr. Dearani also explain the significance of comprehensive evaluations and specialist collaboration in treating HCM. But what obstacles do they encounter in their multidisciplinary efforts? Check out today's episode to discover their approaches to these challenges, and to learn how the latest surgical innovations are transforming treatment options for HCM and beyond.

HCMS Podcast Episode 13.
Optimizing Treatment: The New HCM Guidelines Explained
Dr. Matthew Martinez welcomes Dr. Steve Ommen to discuss the newly unveiled Hypertrophic Cardiomyopathy guidelines. From new medical therapies for obstructive hypertrophic cardiomyopathy, to updates regarding the recommendations for HCM patient exercise, and new insights on sudden cardiac death risk stratification, these two experts break down some of the crucial information contained within the new guidelines, while also highlighting the fundamental similarities and differences between previous guidelines and this newest set. But what are the actual ramifications of these new guidelines to those affected by HCM in all age groups?

HCMS Podcast Episode 12.

Navigating Cardiac Myosin Therapy: Insights for NYHA Class II HCM Patients

When should we make the critical decision to start Cardiac Myosin therapy in NYHA Class II HCM patients? Dr. Patrycja Galazka is joined by Dr. Sara Saberi, and together they dive into the intricate world of Cardiac Myosin Inhibitors, addressing this vital question. In the ever-changing landscape of HCM management, this episode offers a beacon of clarity. Whether you're a healthcare professional dedicated to improving patient outcomes or someone personally navigating the challenges of HCM, our conversation provides essential insights. Join us for a discussion that could reshape your approach to HCM care. 

HCMS Podcast Episode 11.

Gene Therapy and Future of Heart Health with Dr. Day & Dr. Ho

How do you envision the role of gene therapy in shaping the future of cardiac care? In today’s episode, Dr. Sharlene Day engages in an enlightening conversation with Dr. Carolyn Ho, delving into the transformative world of gene therapy. Together, they navigate the complexities of gene therapy's fundamental concepts and potential applications in treating genetic cardiomyopathies and arrhythmia syndromes. Remember, understanding the potential of gene therapy is just the beginning. Collectively, we can pave the way for transformative advancements in treating genetic heart conditions by staying informed and engaged. 

HCMS Podcast Episode 10.

Advances in Nonobstructive HCM with Dr. Lyle and Dr. Kittleson 

Are the symptoms of nonobstructive hypertrophic cardiomyopathy (nHCM) holding patients back from living their fullest lives? Join Dr. Melissa Lyle and Dr. Michelle Kittleson as they unravel the mysteries of nHCM symptoms like congestion, angina, and exercise intolerance. How can we better manage these symptoms and pave the way for improved quality of life? Tune in as they explore innovative solutions, from advanced therapies to cutting-edge gene editing technologies like CRISPR, in the quest for better patient outcomes. Let's uncover the path to empowerment for nHCM patients together. 

HCMS Podcast Episode 9.

Dr. Coats& Dr. Moon on Imaging in HCM 
Cardiologist Dr. Caroline Coats is talking with with Dr. James Moon, the CEO of Mycardium AI Ltd, and a distinguished Professor of Cardiology at University College London. Dr. Moon’s groundbreaking work in cardiac MRI, especially in hypertrophic cardiomyopathy, has changed the way professionals understand and diagnose heart conditions. Today, we’re delving into his wealth of knowledge and experience on imaging in HCM.

HCMS Podcast Episode 8.

Dr. Ayers & Dr. Owens on Myosin Inhibitors 

Our topic of discussion today with Dr. Ayers and Dr. Owens is a critical one that impacts the world of cardiology and beyond cardiac myosin inhibitors. This cutting-edge area of research has the potential to revolutionize the way we approach cardiac diseases, and our experts are here to shed light on the latest developments, breakthroughs, and implications for patients and athletes alike. 

HCMS Podcast Episode 7.

2023 HCMS Sessions Oral Abstract Presentations 

Dr. Robyn Bryde and Dr. Bradley Lander interview each presenting author of the selected abstracts to tell us more about their HCM research.  These abstract presentations were selected to encore at the 2023 HCMS Scientific Sessions on October 6: 

Predictors of appropriate ICD discharges and the additive role of late gadolinium enhancement in hypertrophic cardiomyopathy - Presented by: Srekar Ravi, MD and Said Alsidawi, MD

Cumulative long-term efficacy and safety of mavacamten treatment in nonobstructive hypertrophic cardiomyopathy: updated interim analysis from the MAVERICK cohort of the MAVA-long-term extension (LTE) study up to 120 weeks - Presented by: Anjali Owens, MD

Classifying pathogenicity of TPM1 variants of unknown significance using in vitro and in silico approaches - Presented by: Stuart Campbell, MD.

HCMS Podcast Episode 6.

HCM Exercise Prescription with Dr. Michael Emery

n this episode, Cardiologist Dr. Robyn Bryde engages in an insightful conversation with Dr. Michael Emery. They delve into the crucial topic of exercise restrictions in HCM, exploring the art of crafting exercise prescriptions, counseling athletes and enthusiasts with HCM, and ensuring their safe participation in sports. Tune in for expert insights into this vital aspect of HCM management. Dr. Emery is an associate professor of medicine at the Cleveland Clinic Learner College of Medicine. He’s also the Co-Director of the sports cardiology center at Cleveland Clinic and has a background in exercise physiology.

HCMS Podcast Episode 5.

What's Next for Non-obstructive Hypertrophic Cardiomyopathy

Host Dr. Eli Friedman chats with Dr. Ahmad Masri, of Oregan Health Sciences University Hypertrophic Cardiomyopathy Center. Dr. Friedman and Dr. Masri are good friends and former coworkers, and today they’re talking about finding treatment for patients with non-obstructive Hypertrophic Cardiomyopathy, specifically focusing on drugs on clinical trials and Cardiac Mitotrope Ninerafaxstat. Join us in this gripping episode as we dive into the world of non-obstructive Hypertrophic Cardiomyopathy with two experts who are on a mission to unravel its mysteries. Dr. Friedman and Dr. Masri share their insights on groundbreaking clinical trials and the potential game-changer, Cardiac Mitotrope Ninerafaxstats. Together, we'll explore the challenges, the breakthroughs, and how science is paving the way for a brighter future in cardiac care! 

HCMS Podcast Episode 4.
HCM Care Evolution 

Dr. Bradley Lander chats with Lisa Salberg, the founder of the HCMA, the Hypertrophic Cardiomyopathy Association. Since 1996, Lisa has been on a journey to educate, advocate, and support other patients based on her experience with HCM. By tuning in, you'll unwrap how HCM centers of excellence strive to provide holistic patient care, optimize treatment strategies, and incorporate mental health support, ultimately aiming to enhance the quality of life for those living with this complex genetic heart condition.

HCMS Podcast Episode 3.
Athletes with HCM: Breakthrough Study for Vigorous Exercise

Cardiologist Dr. Robyn Bryde interviews Dr. Matthew Martinez, the Director of Sports Cardiology and Hypertrophic Cardiomyopathy at Morristown Medical Center in New Jersey. Recorded from the Care of the Athletic Heart Conference, they discuss the effects of vigorous exercise on patients with hypertrophic cardiomyopathy (HCM). Historically, patients with HCM were advised to restrict exercise, but recent studies suggest that exercise may not worsen the condition. Dr. Martinez presents findings from a groundbreaking study involving 76 elite athletes with HCM, highlighting the importance of shared decision-making and expert consultation in developing exercise plans for these patients.

HCMS Podcast Episode 2.
Outcomes of Septal Reduction Therapies in Patients with HCM

Professor of medicine and director of the HCM Center at Westchester Medical Center in New York, Dr. Srihari Naidu, speaks with Haslam Family Endowed Chair in Cardiovascular Medicine, Dr. Milind Desai. Dr. Desai discusses his article published in the Journal of the American College of Cardiology, which looks at the long-term outcomes of septal reduction therapies in Medicare patients with obstructive hypertrophic cardiomyopathy.